Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

An observational analysis finds the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have ...

The Coit House in Buffalo unveiled new artwork Friday night highlighting maternal awareness. The renowned Buffalo artist, ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Media maven Oprah Winfrey stirred controversy during a recent “The Oprah Podcast” episode with Yale University obesity medicine physician Dr.

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...